Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Investigational Therapeutics for the Treatment of COVID-19 in Hospitalized Adults
NCT04280705Phase 3Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Feb 2020
- Primary completion
- May 2020
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 10
01
Overview
A Phase 3 trial of remdesivir in coronavirus disease 2019 (COVID-19), sponsored by National Institute of Allergy and Infectious Diseases. Started Feb 2020; status: completed.
02
Drugs
remdesivir
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04280705.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04280705.